A Study of LY2951742 in Participants With Chronic Cluster Headache

Status:	Active, not recruiting
Conditions:	Migraine Headaches
Therapuetic Areas:	Neurology
Healthy:	No
Age Range:	18 - 65
Updated:	9/29/2018
Start Date:	June 18, 2015
End Date:	July 22, 2019

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache

The main purpose of this study is to evaluate the efficacy of the study drug known as
LY2951742 in participants with chronic cluster headache.

Inclusion Criteria:

- Participants with a history of chronic cluster headache occurring without a remission
period, or with remissions lasting <1 month, for at least 1 year.

- Participants are able to distinguish cluster headache attacks from other headaches.

Exclusion Criteria:

- Current enrollment in or discontinuation within the last 30 days from, a clinical
trial involving any investigational drug or device.

- Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP)
antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF).

- Are taking indomethacin and/or are suspected of having another distinct trigeminal
autonomic cephalalgia.

- A history of migraine variants that could implicate or could be confused with
ischemia.

- Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
proteins.

- A history or presence of other medical illness that indicates a medical problem that
would preclude study participation.

- Evidence of significant active or unstable psychiatric disease, in the opinion of the
investigator.

- Women who are pregnant or nursing.

We found this trial at

sites

Stanford University Hospital

Stanford, California 94303

Principal Investigator: Nada Hindiyeh

Phone: 650-497-6810

from

Stanford, CA